TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Vitamin B12 Fortified Milk Supplementation During Pregnancy and 6 Month Postpartum to Improve B12 Status and Child Development
Brief Summary: Impaired vitamin B12 (B12) status during pregnancy is associated with increased risk of birth defects and common complications (e.g. intrauterine growth restriction, neural tube defects), and possibly immune function impairment. The newborns and infants of B12-deficient mothers have low B12 stores at birth, further exacerbated by a very low concentration of B12 in breast milk that may hinder their growth and development. In regions such as Bangladesh, many women of reproductive age have inadequate B12 status, probably due to low intake of animal source food. Vitamin B12 intake and status in pregnancy and lactation is potentially insufficient to prevent impaired child development and immune function related to inadequate B12 status. The investigators hypothesize that prolonged vitamin B12 supplementation through fortified milk starting from early pregnancy up to 6 mo-postpartum will improve: (1) biomarkers of vitamin B12 status in mothers-infant pairs (2) vaccine specific adaptive immunity in infants; (3) neurological and cognitive function in infants.


Options:
A: Arm Label: Vitamin B12; Type: EXPERIMENTAL; Interventions: Dietary Supplement: cobalamin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: cobalamin; Assigned to Arm(s): Vitamin B12 | Intervention Type: DIETARY_SUPPLEMENT; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Vitamin B12-fortified UHT milk; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin B12 fortified UHT milk | Arm Label: Plain UHT milk; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Plain UHT milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12 fortified UHT milk; Assigned to Arm(s): Vitamin B12-fortified UHT milk | Intervention Type: DIETARY_SUPPLEMENT; Name: Plain UHT milk; Assigned to Arm(s): Plain UHT milk
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Folic Acid | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Folic acid and vitamin B12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): C | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid and vitamin B12; Assigned to Arm(s): D
D: Arm Label: Vitamin B12; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): Vitamin B12 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Personalised Physical Training Associated With Usual Management Versus Usual Management Alone on Fatigue and Recovery After Minor Stroke: Randomised Controlled Trial
Brief Summary: After a minor stroke, patients frequently report complaints such as fatigue and difficulty with certain everyday motor tasks, leading to a marked deterioration in their quality of life. The aim of this study is to show that the implementation of a personalised physical activity programme, starting 1 month after the hospitalisation for minor stroke, significantly decreases the frequency of fatigue in these patients, in comparison with usual management "in real life"..


Options:
A: Arm Label: Intensive group; Type: EXPERIMENTAL; Interventions: Procedure: Cognitive rehabilitation | Arm Label: Conventional group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cognitive rehabilitation | Intervention Type: PROCEDURE; Name: Cognitive rehabilitation; Assigned to Arm(s): Conventional group, Intensive group
B: Arm Label: usual management; Type: OTHER; Interventions: Other: no physical activity | Arm Label: physical training; Type: EXPERIMENTAL; Interventions: Other: physical activity | Intervention Type: OTHER; Name: no physical activity; Assigned to Arm(s): usual management | Intervention Type: OTHER; Name: physical activity; Assigned to Arm(s): physical training
C: Arm Label: High Therapy Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: Moderate Therapy Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: Low Therapy Dose; Type: EXPERIMENTAL; Interventions: Behavioral: Accelerated Skill Acquisition Program (ASAP) | Arm Label: Active Monitoring; Type: OTHER; Interventions: Behavioral: Active Monitoring | Intervention Type: BEHAVIORAL; Name: Accelerated Skill Acquisition Program (ASAP); Assigned to Arm(s): High Therapy Dose, Low Therapy Dose, Moderate Therapy Dose | Intervention Type: BEHAVIORAL; Name: Active Monitoring; Assigned to Arm(s): Active Monitoring
D: Arm Label: Higher-intensity RT group; Type: EXPERIMENTAL; Interventions: Device: RT, Behavioral: Conventional rehabilitation (CR) | Arm Label: Lower-intensity RT group; Type: EXPERIMENTAL; Interventions: Device: RT, Behavioral: Conventional rehabilitation (CR) | Arm Label: Conventional rehabilitation (CR) group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional rehabilitation (CR) | Intervention Type: DEVICE; Name: RT; Assigned to Arm(s): Higher-intensity RT group, Lower-intensity RT group | Intervention Type: BEHAVIORAL; Name: Conventional rehabilitation (CR); Assigned to Arm(s): Conventional rehabilitation (CR) group, Higher-intensity RT group, Lower-intensity RT group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Personalised Physical Training Associated With Usual Management Versus Usual Management Alone on Fatigue and Recovery After Minor Stroke: Randomised Controlled Trial
Brief Summary: After a minor stroke, patients frequently report complaints such as fatigue and difficulty with certain everyday motor tasks, leading to a marked deterioration in their quality of life. The aim of this study is to show that the implementation of a personalised physical activity programme, starting 1 month after the hospitalisation for minor stroke, significantly decreases the frequency of fatigue in these patients, in comparison with usual management "in real life"..


Options:
A: Intervention Type: BEHAVIORAL; Name: Conventional UK Physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased intensity of UK conventional physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: UK conventional physical therapy plus functional strength training; Assigned to Arm(s): N/A
B: Arm Label: usual management; Type: OTHER; Interventions: Other: no physical activity | Arm Label: physical training; Type: EXPERIMENTAL; Interventions: Other: physical activity | Intervention Type: OTHER; Name: no physical activity; Assigned to Arm(s): usual management | Intervention Type: OTHER; Name: physical activity; Assigned to Arm(s): physical training
C: Arm Label: High Intensity; Type: EXPERIMENTAL; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and neuromuscular electrical stimulation | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bilateral movements and sham electrical stimulation | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): High Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and neuromuscular electrical stimulation; Assigned to Arm(s): Low Intensity | Intervention Type: BEHAVIORAL; Name: Bilateral movements and sham electrical stimulation; Assigned to Arm(s): Control
D: Arm Label: real tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham tDCS, real tDCS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
Brief Summary: The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.


Options:
A: Arm Label: Arm A: Chemotherapy + Bevacizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Chemotherapy, Drug: Placebos | Arm Label: Arm B: Chemotherapy + Bevacizumab + Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Atezolizumab, Drug: Chemotherapy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo, Arm B: Chemotherapy + Bevacizumab + Atezolizumab | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Arm A: Chemotherapy + Bevacizumab + Placebo
B: Arm Label: Arm I; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Drug: cyclophosphamide, Drug: celecoxib | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Arm I, Arm II | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): Arm II
C: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
D: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Drug: apatinib | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: apatinib; Assigned to Arm(s): experimental group | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer
Brief Summary: The study is to investigate the efficacy and safety of apatinib in patients with advanced ovarian cancer,who has received second-line chemotherapy and failed.


Options:
A: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo
B: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Drug: apatinib | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: apatinib; Assigned to Arm(s): experimental group | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): control group
C: Arm Label: Lead-in Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Randomized Stage - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-Label Extension - cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Arm Label: A. Non-Randomized Expansion (NRE) Cohort - Ovarian; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): A. Non-Randomized Expansion (NRE) Cohort - Ovarian, Lead-in Stage - cabozantinib (XL184), Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg, Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg, Open-Label Extension - cabozantinib (XL184), Randomized Stage - cabozantinib (XL184) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Randomized Stage - placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Arm Label: Aflibercept; Type: EXPERIMENTAL; Interventions: Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Assigned to Arm(s): Aflibercept, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SEGA - SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke - a Randomized Comparative Effectiveness Trial.
Brief Summary: Objectives:

This study aims to estimate overall treatment benefit (improvement in disability) among acute ischemic stroke patients that are randomized to General Anesthesia (GA) compared with Sedation (CS) during endovascular therapy. Assess safety (as measured by incidence of symptomatic intracranial hemorrhage); rates of Endovascular therapy (EVT) procedural complications, reperfusion; and quality of life.

Hypothesis:

GA during EVT for acute ischemic stroke improves functional outcomes at 90 days compared to sedation.


Options:
A: Arm Label: Local anesthesia/conscious sedation; Type: OTHER; Interventions: Procedure: Local anesthesia/concious sedation, Procedure: Spontaneous breath | Arm Label: General anesthesia; Type: OTHER; Interventions: Procedure: General anesthesia, Procedure: Controlled ventilation | Intervention Type: PROCEDURE; Name: General anesthesia; Assigned to Arm(s): General anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia/concious sedation; Assigned to Arm(s): Local anesthesia/conscious sedation | Intervention Type: PROCEDURE; Name: Spontaneous breath; Assigned to Arm(s): Local anesthesia/conscious sedation | Intervention Type: PROCEDURE; Name: Controlled ventilation; Assigned to Arm(s): General anesthesia
B: Arm Label: Sedation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sedation, Procedure: Intra-arterial Thrombectomy | Arm Label: General Anesthesia; Type: ACTIVE_COMPARATOR; Interventions: Drug: General Anesthesia (GA), Procedure: Intra-arterial Thrombectomy | Intervention Type: DRUG; Name: Sedation; Assigned to Arm(s): Sedation | Intervention Type: DRUG; Name: General Anesthesia (GA); Assigned to Arm(s): General Anesthesia | Intervention Type: PROCEDURE; Name: Intra-arterial Thrombectomy; Assigned to Arm(s): General Anesthesia, Sedation
C: Arm Label: GA with mild hypercarbia (GAH); Type: ACTIVE_COMPARATOR; Interventions: Other: Tight control of end-tidal CO2 levels | Arm Label: GA with normocarbia (GAN); Type: ACTIVE_COMPARATOR; Interventions: Other: Tight control of end-tidal CO2 levels | Intervention Type: OTHER; Name: Tight control of end-tidal CO2 levels; Assigned to Arm(s): GA with mild hypercarbia (GAH), GA with normocarbia (GAN)
D: Arm Label: General Anesthesia; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Local Anesthesia; Type: EXPERIMENTAL; Interventions: Procedure: Local anesthesia | Intervention Type: PROCEDURE; Name: Local anesthesia; Assigned to Arm(s): Local Anesthesia

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Upper Airway Training for Treatment of Snoring Using Smartphone Application
Brief Summary: The objective of this study is to reduce the incidence or intensity of snoring in a patient population of known simple snorers without sleep apnea using smartphone based application which allows participants to play voice controlled games using various articulations resulting in tongue base movements.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Oropharyngeal exercises | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Behavioral: Respiratory exercises, nasal dilator, nasal lavage | Intervention Type: BEHAVIORAL; Name: Oropharyngeal exercises; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Respiratory exercises, nasal dilator, nasal lavage; Assigned to Arm(s): 2
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Smart phone game play | Intervention Type: OTHER; Name: Smart phone game play; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: 1; Type: SHAM_COMPARATOR; Interventions: Behavioral: Deep breathing, bilateral alternate chewing, nasal lavage | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Oropharyngeal exercises | Intervention Type: BEHAVIORAL; Name: Deep breathing, bilateral alternate chewing, nasal lavage; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Oropharyngeal exercises; Assigned to Arm(s): 2
D: Arm Label: placebo exercices; Type: PLACEBO_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Arm Label: phonoaudiologic therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Continuous Positive Airway Pressure (CPAP); Assigned to Arm(s): phonoaudiologic therapy, placebo exercices

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants
Brief Summary: Comparison between the safety and efficacy of oral paracetamol and oral ibuprofen in treatment of Patent Ductus Arteriosus (PDA) in premature infants


Options:
A: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen
B: Arm Label: early ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Early ibuprofen | Arm Label: Late Ibuprofen expectant group (placebo); Type: OTHER; Interventions: Other: Late ibuprofen expectant group (placebo) | Intervention Type: DRUG; Name: Early ibuprofen; Assigned to Arm(s): early ibuprofen | Intervention Type: OTHER; Name: Late ibuprofen expectant group (placebo); Assigned to Arm(s): Late Ibuprofen expectant group (placebo)
C: Arm Label: ibuprofen group; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: paracetamol group; Type: EXPERIMENTAL; Interventions: Drug: paracetamol | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen group | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol group
D: Arm Label: Infant treated with high dose ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Infant treated with high dose ibuprofen

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants
Brief Summary: Comparison between the safety and efficacy of oral paracetamol and oral ibuprofen in treatment of Patent Ductus Arteriosus (PDA) in premature infants


Options:
A: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen
B: Arm Label: ACS (Group 1); Type: ACTIVE_COMPARATOR; Interventions: Drug: Betamethason Sodium Phosphate | Arm Label: Placebo (Group 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Betamethason Sodium Phosphate; Assigned to Arm(s): ACS (Group 1) | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo (Group 2)
C: Arm Label: ibuprofen group; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: paracetamol group; Type: EXPERIMENTAL; Interventions: Drug: paracetamol | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): ibuprofen group | Intervention Type: DRUG; Name: paracetamol; Assigned to Arm(s): paracetamol group
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Remifentanyl | Intervention Type: DRUG; Name: Remifentanyl; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis - a Multicentric Randomized Controlled Group Sequential Trial
Brief Summary: Infective endocarditis (IE) is associated with high hospital mortality for various reasons; one of them is circulatory failure in patients who undergo cardiac surgery for IE. One discussed reason underlying circulatory failure during surgery is the release of vasodilatatory mediators and cytokines. This study examines the efficacy and safety of a hemoadsorption filter which is approved for the reduction of the concentration of cytokines in the bloodstream.


Options:
A: Arm Label: Interventional group; Type: EXPERIMENTAL; Interventions: Device: hemoadsorber for removal of cytokines | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: hemoadsorber for removal of cytokines; Assigned to Arm(s): Interventional group
B: Arm Label: CytoSorb; Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): CytoSorb
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Sevoflurane Group; Type: N/A; Interventions: Drug: Sevoflurane | Arm Label: Not Sevoflurane Group; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane Group

Answer: A